

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>An overview of cutaneous T cell lymphomas | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-1882/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-1882" />
    
            <meta name="description" content="Read the original article in full on F1000Research: An overview of cutaneous T cell lymphomas" />
    
            <meta name="og:title" content="F1000Research Article: An overview of cutaneous T cell lymphomas.">
            <meta name="og:description" content="Read the latest article version by Nooshin Bagherani, Bruce R. Smoller, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9504">
            <meta name="article-id" content="8829">
            <meta name="dc.title" content="An overview of cutaneous T cell lymphomas">
            <meta name="dc.description" content="Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin&rsquo;s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. They typically afflict adults with a median age of 55 to 60 years, and the annual incidence is about 0.5 per 100,000. Mycosis fungoides, S&amp;eacute;zary syndrome, and primary cutaneous peripheral T cell lymphomas not otherwise specified are the most important subtypes of CTCL. CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we summarize advances which have been achieved in these fields.">
            <meta name="dc.subject" content="cutaneous T cell lymphoma, mycosis fungoides, S&eacute;zary syndrome">
            <meta name="dc.creator" content="Bagherani, Nooshin">
            <meta name="dc.creator" content="Smoller, Bruce R.">
            <meta name="dc.date" content="2016/07/28">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.8829.1">
            <meta name="dc.source" content="F1000Research 2016 5:1882">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="cutaneous T cell lymphoma">
            <meta name="prism.keyword" content=" mycosis fungoides">
            <meta name="prism.keyword" content=" S&eacute;zary syndrome">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/07/28">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="1882">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.8829.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-1882">
            <meta name="citation_title" content="An overview of cutaneous T cell lymphomas">
            <meta name="citation_abstract" content="Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin&rsquo;s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. They typically afflict adults with a median age of 55 to 60 years, and the annual incidence is about 0.5 per 100,000. Mycosis fungoides, S&amp;eacute;zary syndrome, and primary cutaneous peripheral T cell lymphomas not otherwise specified are the most important subtypes of CTCL. CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we summarize advances which have been achieved in these fields.">
            <meta name="citation_description" content="Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin&rsquo;s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. They typically afflict adults with a median age of 55 to 60 years, and the annual incidence is about 0.5 per 100,000. Mycosis fungoides, S&amp;eacute;zary syndrome, and primary cutaneous peripheral T cell lymphomas not otherwise specified are the most important subtypes of CTCL. CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we summarize advances which have been achieved in these fields.">
            <meta name="citation_keywords" content="cutaneous T cell lymphoma, mycosis fungoides, S&eacute;zary syndrome">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Nooshin Bagherani">
            <meta name="citation_author_institution" content="Taha Physicians' Building, Khoramshahr, Khuzestan Province, Iran">
            <meta name="citation_author" content="Bruce R. Smoller">
            <meta name="citation_author_institution" content="Department of Dermatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA">
            <meta name="citation_publication_date" content="2016/07/28">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="1882">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.8829.1">
            <meta name="citation_firstpage" content="1882">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-1882/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-1882.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9504 /> <input type=hidden id=articleId name=articleId value=8829 /> <input type=hidden id=xmlUrl value="/articles/5-1882/v1/xml"/> <input type=hidden id=xmlFileName value="-5-1882-v1.xml"> <input type=hidden id=article_uuid value=070b238f-64d8-44d0-847f-33ff210a1f0a /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="An overview of cutaneous T cell lymphomas"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.8829.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.8829.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-1882"
  },
  "headline": "An overview of cutaneous T cell lymphomas",
  "datePublished": "2016-07-28T12:29:16",
  "dateModified": "2016-07-28T12:29:16",
  "author": [
    {
      "@type": "Person",
      "name": "Nooshin Bagherani"
    },    {
      "@type": "Person",
      "name": "Bruce R. Smoller"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin&rsquo;s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. They typically afflict adults with a median age of 55 to 60 years, and the annual incidence is about 0.5 per 100,000. Mycosis fungoides, S&amp;eacute;zary syndrome, and primary cutaneous peripheral T cell lymphomas not otherwise specified are the most important subtypes of CTCL. CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we summarize advances which have been achieved in these fields."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-1882.html",
            "name": "An overview of cutaneous T cell lymphomas"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> An overview of cutaneous T cell lymphomas </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9504 data-id=8829 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8829.1" data-recommended="" data-doi="10.12688/f1000research.8829.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-1882/v1/pdf?article_uuid=070b238f-64d8-44d0-847f-33ff210a1f0a" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-8829-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-8829-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-8829-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bagherani N and Smoller BR. An overview of cutaneous T cell lymphomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1882 (<a class=new-orange href="https://doi.org/10.12688/f1000research.8829.1" target=_blank>https://doi.org/10.12688/f1000research.8829.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-8829-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=8829 id=track-article-signin-8829 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8829?target=/articles/5-1882.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9504 /> <input name=articleId type=hidden value=8829 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>An overview of cutaneous T cell lymphomas</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:nooshinbagherani@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Nooshin Bagherani</span></a><sup>1</sup>,&nbsp;</span><span class="">Bruce R. Smoller<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:nooshinbagherani@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Nooshin Bagherani</span></a><sup>1</sup>,&nbsp;</span><span class="">Bruce R. Smoller<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 28 Jul 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.8829.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Taha Physicians' Building, Khoramshahr, Khuzestan Province, Iran<br/> <sup>2</sup> Department of Dermatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=15892-14987></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=15891-14988></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin’s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. They typically afflict adults with a median age of 55 to 60 years, and the annual incidence is about 0.5 per 100,000. Mycosis fungoides, S&eacute;zary syndrome, and primary cutaneous peripheral T cell lymphomas not otherwise specified are the most important subtypes of CTCL. CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we summarize advances which have been achieved in these fields. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> cutaneous T cell lymphoma, mycosis fungoides, Sézary syndrome </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Nooshin Bagherani (<a href="mailto:nooshinbagherani@yahoo.com">nooshinbagherani@yahoo.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Nooshin Bagherani </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Bagherani N and Smoller BR. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bagherani N and Smoller BR. An overview of cutaneous T cell lymphomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1882 (<a href="https://doi.org/10.12688/f1000research.8829.1" target=_blank>https://doi.org/10.12688/f1000research.8829.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 28 Jul 2016, <b>5</b>(F1000 Faculty Rev):1882 (<a href="https://doi.org/10.12688/f1000research.8829.1" target=_blank>https://doi.org/10.12688/f1000research.8829.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 28 Jul 2016, <b>5</b>(F1000 Faculty Rev):1882 (<a href="https://doi.org/10.12688/f1000research.8829.1" target=_blank>https://doi.org/10.12688/f1000research.8829.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e161>Introduction</h2><p class="" id=d25988e164>In 1806, Alibert initially described mycosis fungoides (MF) as the infiltration of skin by lymphocytes. In 1974, Edelson used the term “cutaneous T cell lymphomas” (CTCLs) for MF and its leukemic variant, Sézary syndrome (SS), which are the major types of CTCL<sup><a href="#ref-1">1</a></sup>. Nowadays, the CTCLs, which are characterized by infiltration of malignant monoclonal T lymphocytes in the skin, are considered a heterogeneous group of extranodal non-Hodgkin’s lymphomas<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. Approximately 25% to 40% of non-Hodgkin’s lymphoma cases involve extranodal sites. The skin is the most common site after the gastrointestinal system<sup><a href="#ref-4">4</a></sup>. The annual incidence of CTCL is about 0.5 per 100,000, and men are more involved than women (1.6:1 to 2.0:1)<sup><a href="#ref-1">1</a></sup>. They typically afflict adults with a median age of 55 to 60 years<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d25988e193>In 1975, for the first time, the North American Mycosis Fungoides Cooperative Study Group classified the CTCLs on the basis of a tumor-node-metastasis (TNM) system. Thereafter, the classification was modified and updated by the CTCL workshop to the one used today, known as the Bunn and Lambert system<sup><a href="#ref-1">1</a></sup>. The International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer classified MF and SS according to clinical, pathological, biological, and immunological features<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d25988e204>MF, SS, and primary cutaneous peripheral T cell lymphomas not otherwise specified (PCTCL - NOS) are among the most important subtypes of the CTCLs<sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>. MF is the commonest type of CTCLs, representing 44% to 62% of cases<sup><a href="#ref-9">9</a></sup>. MF restricted to the skin has an indolent progression passing from macule and patch stage to infiltrated plaque and tumor stage (<a href="#f1">Figure 1</a>)<sup><a href="#ref-5">5</a>,<a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup> in sun-protected body sites<sup><a href="#ref-12">12</a></sup>. SS is defined as an aggressive leukemic-phase type of MF<sup><a href="#ref-11">11</a></sup>, clinically characterized by erythroderma and generalized lymphadenopathy<sup><a href="#ref-13">13</a></sup>. PCTCL-NOS can present with a solitary red-violaceous tumor-like nodule or scattered multifocal or diffuse nodules on any part of the body, which mostly become ulcerated and infected. Rapid cutaneous dissemination and systemic involvement are key features of this class of CTCL<sup><a href="#ref-8">8</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure1.gif"><img alt="3b0e5a3b-af13-42bc-b794-54dd9be57490_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure1.gif"></a><div class=caption><h3>Figure 1. Mycosis fungoides in a 40-year-old man manifested as generalized atrophic patches.</h3></div></div><p class="" id=d25988e263>At the early stages, CTCLs are often misdiagnosed as benign skin conditions<sup><a href="#ref-1">1</a>,<a href="#ref-9">9</a>,<a href="#ref-13">13</a>–<a href="#ref-17">17</a></sup>. Their most important differential diagnoses have been listed in <a href="#T1">Table 1</a>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. The most important differential diagnoses of the cutaneous T cell lymphomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25988e293 class=n-a></a><tbody><a name=d25988e295 class=n-a></a><tr><a name=d25988e297 class=n-a></a><td colspan=1 rowspan=1><a name=d25988e299 class=n-a></a>All kinds of dermatitis and eczema<sup><a href="#ref-1">1</a>,<a href="#ref-9">9</a>,<a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup> <br class=br>Adverse drug reactions<sup><a href="#ref-13">13</a></sup> <br class=br>Parapsoriasis<sup><a href="#ref-9">9</a></sup> <br class=br>Psoriasis<sup><a href="#ref-1">1</a>,<a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup> <br class=br>Lichen planus<sup><a href="#ref-16">16</a></sup> <br class=br>Morphea<sup><a href="#ref-16">16</a></sup> <br class=br>Panniculitis<sup><a href="#ref-17">17</a></sup> <br class=br>Folliculitis<sup><a href="#ref-14">14</a></sup> <br class=br>Pityriasis lichenoides chronica<sup><a href="#ref-14">14</a></sup> <br class=br>Pityriasis lichenoides et varioliformis acuta<sup><a href="#ref-14">14</a></sup> <br class=br>Pigmented purpuric dermatoses<sup><a href="#ref-14">14</a></sup> <br class=br>Vitiligo<sup><a href="#ref-14">14</a></sup> <br class=br>Lymphomatoid papulosis<sup><a href="#ref-9">9</a></sup> </td></tr></tbody></table></div><p class="" id=d25988e401>In most patients with CTCL, the histologic features are subtle, so that the differentiation of these disorders from benign inflammatory diseases is difficult<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. Haloed lymphocytes, exocytosis, epidermotropism, Pautrier’s microabscess, large hyperconvoluted, hyperchromatic lymphocytes in the epidermis, and lymphocytes aligned within the basal layer are findings seen in histologic sections of MF (<a href="#f2">Figure 2</a>)<sup><a href="#ref-16">16</a>,<a href="#ref-20">20</a></sup>.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure2.gif"><img alt="3b0e5a3b-af13-42bc-b794-54dd9be57490_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure2.gif"></a><div class=caption><h3>Figure 2. In pathological view, the cutaneous T cell lymphomas are characterized by haloed lymphocytes, exocytosis, epidermotropism, Pautrier’s microabscess, large hyperconvoluted, hyperchromatic lymphocytes in the epidermis, and lymphocytes aligned within the basal layer.</h3><p id=d25988e431><b>Figure 2A</b> (left) A lymphocytic infiltrate is present in the dermis and extending into the overlying epidermis with minimal overlying spongiosis. <b>Figure 2B</b> (center) Lymphocytes with surrounding haloes are present in the epidermis as single cells and small clusters (Pautrier’s microabscesses). There is minimal accompanying spongiosis. <b>Figure 2C</b> (right) Psoriasiform epidermal hyperplasia with epidermotropism of haloed lymphocytes is seen in this case of patch-stage mycosis fungoides.</p></div></div><p class="" id=d25988e446>CTCL is a complicated concept in terms of etiopathogenesis, diagnosis, therapy, and prognosis. Herein, we have summarized advances which have been achieved in these fields.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e452>Etiopathogenesis</h2><p class="" id=d25988e455>Although different views of CTCL etiopathogenesis have been elucidated in depth over the last few decades, the exact mechanism of initiation and progression of this disorder is not yet known<sup><a href="#ref-4">4</a>,<a href="#ref-10">10</a>,<a href="#ref-21">21</a></sup> (<a href="#f3">Figure 3</a>). Although dysregulation of some genes and signaling pathways has been reported in the CTCLs (<a href="#T2">Table 2</a>), their exact role in the pathogenesis of these disorders is unknown<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a>,<a href="#ref-13">13</a>,<a href="#ref-22">22</a>–<a href="#ref-34">34</a></sup>. Most of these aberrations are seen in chromosome 10<sup><a href="#ref-35">35</a></sup>. Recent studies demonstrate ectopic expression of cancer testis genes in the CTCLs. It appears that this gene works through inhibiting apoptosis, inducing resistance to various forms of therapeutic modalities, and contributing to oncogenesis by targeting tumor suppressor genes such as <i>p53</i> and <i>p21</i><sup><a href="#ref-2">2</a></sup>. Deficient expression or function of negative regulators, including SOCS3 and protein tyrosine phosphatases such as SHP1, have been implicated in dysregulation of the Jak-3/STAT pathway and interleukin (IL)-independent proliferation of malignant T cells. The Jak-3/STAT pathway has a role in fighting against CTCLs by promoting production of IL-5, IL-10, IL-17A, and IL-17F; regulating angiogenic factors; and interfering with resistance to histone deacetylase inhibitor (HDACI) therapy<sup><a href="#ref-25">25</a></sup>. An additional report demonstrates pathogenic involvement of the NOTCH1 signaling pathway in the pathogenesis of SS<sup><a href="#ref-13">13</a></sup>. NOTCH includes a family of transmembrane receptors, which play roles in cell differentiation, proliferation, and stemness<sup><a href="#ref-31">31</a></sup>.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure3.gif"><img alt="3b0e5a3b-af13-42bc-b794-54dd9be57490_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9504/3b0e5a3b-af13-42bc-b794-54dd9be57490_figure3.gif"></a><div class=caption><h3>Figure 3. Etiopathogenesis of cutaneous T cell lymphoma. </h3><p id=d25988e526>CTCL, cutaneous T cell lymphoma.</p></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. An alphabetical list of dysregulation of genes and signaling pathways seen in the cutaneous T cell lymphomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25988e544 class=n-a></a><tbody><a name=d25988e546 class=n-a></a><tr><a name=d25988e548 class=n-a></a><td colspan=1 rowspan=1><a name=d25988e550 class=n-a></a>AT-rich interactive domain-containing protein 1A (ARID1A)<sup><a href="#ref-23">23</a></sup> <br class=br>B-Raf proto-oncogene, serine/threonine kinase (BRAF)<sup><a href="#ref-24">24</a></sup> <br class=br>Bromodomain-9 (BRD-9)<sup><a href="#ref-24">24</a></sup> <br class=br>Cancer testis (CT)<sup><a href="#ref-2">2</a></sup> <br class=br>Caspase recruitment domain (CARD11)<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup> <br class=br>C-C chemokine receptor-4 (CCR-4)<sup><a href="#ref-23">23</a></sup> <br class=br>Chromodomain-helicase-DNA-binding protein (CHD)-3<sup><a href="#ref-24">24</a></sup> <br class=br>CREB-binding protein (CREBBP)<sup><a href="#ref-24">24</a></sup> <br class=br>Cyclin-dependent kinase-2 (CDKN-2)<sup><a href="#ref-23">23</a>–<a href="#ref-26">26</a></sup> <br class=br>Cyclooxygenase-2 (COX-2)<sup><a href="#ref-25">25</a></sup> <br class=br>Dynamin-3 (DNM-3)<sup><a href="#ref-22">22</a></sup> <br class=br>Embryonic stem cell regulators<sup><a href="#ref-3">3</a>,<a href="#ref-25">25</a></sup> <br class=br>Eph receptor A4 (EPHA4)<sup><a href="#ref-13">13</a></sup> <br class=br>Forkhead box P3 (FOXP3)<sup><a href="#ref-27">27</a></sup> <br class=br>GATA-binding protein-3 (GATA-3)<sup><a href="#ref-22">22</a>,<a href="#ref-25">25</a></sup> <br class=br>Histone deacetylase-6 (HDAC-6)<sup><a href="#ref-25">25</a></sup> <br class=br>Histone-lysine N-methyltransferase (KMT)-2D or myeloid/lymphoid or mixed-lineage leukemia protein-2 (MLL-2)<sup><a href="#ref-24">24</a></sup> <br class=br>Interleukin-2 receptor common gamma chain (IL-2Rgc)<sup><a href="#ref-3">3</a>,<a href="#ref-25">25</a></sup> <br class=br>Janus kinase-3 (Jak-3)/signal transducers and activators of transcription (STAT)<sup><a href="#ref-25">25</a>,<a href="#ref-28">28</a></sup> <br class=br>KIRD3DL2<sup><a href="#ref-22">22</a></sup> <br class=br>Lysine (K)-specific methyltransferase (KMT)-2C or myeloid/lymphoid or mixed-lineage leukemia protein-3 (MLL-3)<sup><a href="#ref-24">24</a></sup> <br class=br>MYC-associated factor X (MAX)<sup><a href="#ref-25">25</a></sup> <br class=br>Metallothioneins I and II (MTI/II)<sup><a href="#ref-29">29</a></sup> <br class=br>Methylthioadenosine-phosphorylase (MTAP)<sup><a href="#ref-30">30</a></sup> <br class=br>Mitogen-activated protein kinase 1 (MAPK1)<sup><a href="#ref-24">24</a></sup> <br class=br>MYC-binding protein (MYCBP)<sup><a href="#ref-25">25</a></sup> <br class=br>NOTCH1<sup><a href="#ref-13">13</a>,<a href="#ref-31">31</a></sup> <br class=br>Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)<sup><a href="#ref-3">3</a>,<a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup> <br class=br>Nuclear factor of activated T cells (NFAT)<sup><a href="#ref-24">24</a></sup> <br class=br>Phospholipase C gamma 1 (PLCG1)<sup><a href="#ref-23">23</a>,<a href="#ref-32">32</a></sup> <br class=br>P21<sup><a href="#ref-33">33</a></sup> <br class=br>P53<sup><a href="#ref-28">28</a>,<a href="#ref-32">32</a></sup> <br class=br>Phosphatase and tensin homolog (PTEN)<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a>,<a href="#ref-34">34</a></sup> <br class=br>Plastin-3 (PLS-3)<sup><a href="#ref-22">22</a></sup> <br class=br>Protein kinase, CGMP-dependent (PRKG1)<sup><a href="#ref-24">24</a></sup> <br class=br>Receptor tyrosine kinase (RTK)<sup><a href="#ref-13">13</a></sup> <br class=br>Retinoblastoma-1 (RB-1)<sup><a href="#ref-24">24</a></sup> <br class=br>Ribosomal protein S6 kinase-1 (RPS6KA-1)<sup><a href="#ref-23">23</a></sup> <br class=br>Runt-related transcription factor-3 (RUNX-3)<sup><a href="#ref-22">22</a></sup> <br class=br>Src homology region 2 domain-containing phosphatase-1 (SHP1)<sup><a href="#ref-25">25</a></sup> <br class=br>Special AT-rich sequence-binding protein 1 (SATB1)<sup><a href="#ref-29">29</a></sup> <br class=br>SRC proto-oncogene, non-receptor tyrosine kinase (Src kinases)<sup><a href="#ref-25">25</a></sup> <br class=br>Suppressors of cytokine signaling-3 (SOCS3)<sup><a href="#ref-25">25</a></sup> <br class=br>SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin-A4 (SMARC-A4)<sup><a href="#ref-24">24</a></sup> <br class=br>Tet methylcytosine dioxygenase 2 (TET2)<sup><a href="#ref-24">24</a></sup> <br class=br>Thymocyte selection-associated high-mobility group box (TOX)<sup><a href="#ref-22">22</a>,<a href="#ref-25">25</a></sup> <br class=br>Tumor protein p53 (TP53)<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup> <br class=br>Tumor necrosis factor receptor superfamily-1B (TNFRSF-1B)<sup><a href="#ref-30">30</a></sup> <br class=br>Twist<sup><a href="#ref-22">22</a></sup> <br class=br>Zinc finger E-box-binding homeobox 1 (ZEB1)<sup><a href="#ref-23">23</a></sup> </td></tr></tbody></table></div><p class="" id=d25988e916>The loss of heterozygosity of phosphatase and tensin homolog (PTEN) in MF has been reported, but the significance of the finding remains unclear. In one study, a statistically significant decrease in the percentage of cells retaining PTEN and altered staining intensity were shown in MF from patch to plaque stage, but this attenuation was not significant in tumor stage in comparison with plaque stage<sup><a href="#ref-32">32</a></sup>. The mRNA expression of a subfamily of receptor tyrosine kinase (RTK) is high in SS but not in other types of CTCLs<sup><a href="#ref-13">13</a></sup>.</p><p class="" id=d25988e928>TOX is a transcription factor with a role in the development of CD4<sup>+</sup> T cells, including downstream effects on the expression of <i>RUNX 3</i>, a well-known tumor suppressor gene. Studies show that the overexpression of TOX and its protein product is associated with thicker lesions of MF, disease progression, and poor prognosis. Furthermore, dysregulation of this gene is reported in lesions and peripheral blood mononuclear cells of cases with SS<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d25988e941>Patients with CTCL show a distinct microRNA (miRNA) expression profile. Studies have shown that miR-21 and miR-155 are associated with poor prognosis and aggressive behavior by interfering with resistance to apoptosis and promoting malignant proliferation, respectively. On the other hand, the expression of miR-22, a tumor suppressor, is downregulated in SS. It appears that Jak-3/STAT is responsible for the loss of miR-22 expression<sup><a href="#ref-25">25</a></sup>. miR-16 is another non-coding microRNA that induces cellular senescence and is downregulated in CTCLs<sup><a href="#ref-33">33</a></sup>. Studies have shown that miRNAs inhibit the expression of many oncogenes such as <i>MAX</i>, <i>MYCBP</i>, nuclear receptor coactivator-1 (<i>NCOA-1</i>), and cyclin-dependent kinase-6 (<i>CDK-6</i>)<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d25988e969>A role for IL-2Rgc-signaling cytokines, including IL-2, IL-4, IL-7, IL-15, and IL-21, has been suggested in the pathogenesis of CTCLs<sup><a href="#ref-25">25</a></sup>. IL-12 plays a role as a potent anti-tumor agent. Its expression is decreased during tumoral-stage MF<sup><a href="#ref-36">36</a></sup>. On the other hand, in lesional skin of CTCLs, increased expression of IL-9 that is regulated by STAT3/5 and silencing of STAT5 has been reported<sup><a href="#ref-37">37</a></sup>. Additionally, upregulation of CC chemokine receptor 6 (CCR6)<sup><a href="#ref-38">38</a></sup> and CCR7<sup><a href="#ref-3">3</a></sup> has been reported in CTCLs and alleged to be responsible for spreading malignant T cells to sentinel lymph nodes, the bloodstream, and internal organs. Chemokine (C-X-C motif) ligand 12 (CXCL12) belongs to the superfamily of chemokines that is expressed on endothelial and stromal cells in different organs. Most hematopoietic cells such as CD34<sup>+</sup> progenitor cells and CD4<sup>+</sup> T cells express CXCR4, the receptor of this chemokine. This receptor plays a role in chemotaxis, invasion, angiogenesis, and proliferation. The role of the CXCR4/CXCL12 axis has been implicated in the pathogenesis of MF<sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d25988e1003>In CTCLs, malignant T cells display activation of the T cell receptor (TCR) pathway, which leads to TCR-dependent T helper 2 (Th2) cytokines such as IL-4 and IL-13 and resistance to natural mechanisms that prevent uncontrolled proliferation, such as Fas cell surface death receptor (FAS)-mediated apoptosis and transforming growth factor-beta-mediated growth suppression<sup><a href="#ref-12">12</a></sup>. Regulatory T cells with a CD4<sup>+</sup> CD25<sup>+</sup> phenotype comprise about 5% to 10% of peripheral T cells and play a role in tumor immunology. The role of these cells in CTCLs is controversial. Most studies have shown that, in CTCLs, a high count of FOXP3<sup>+</sup> regulatory T cells is correlated with improved prognosis. This finding is completely opposite to that of studies on the role of these cells in solid tumors<sup><a href="#ref-27">27</a></sup>.</p><p class="" id=d25988e1023>Studies have shown that CD26 is able to cleave and inactivate CXCL12; hence, its lack of expression in CTCLs results in enhanced CXCL12-dependent chemotaxis<sup><a href="#ref-10">10</a></sup>. On the other hand, CD164 is significantly overexpressed on CD4<sup>+</sup> lymphocytes in SS. It seems that this factor can be a diagnostic parameter and a potential target for therapeutic approaches in SS<sup><a href="#ref-39">39</a></sup>. These are zinc-dependent enzymes implicated in gene regulation and in the modulation of numerous cellular pathways, including proliferation, differentiation, apoptosis, and migration. Aberration in the activity of these enzymes and their mutations has been reported in CTCLs<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d25988e1041>In MF, the malignant cells migrate to the skin by using the ligand E-selectin on endothelial cells by the expression of a marker for skin homing, cutaneous lymphocyte-associated antigen (CLA). The ability of CLA to mediate leukocyte homing to the skin is dependent on specific chemokine receptor-ligand interactions. One of these interactions occurs through chemokine receptor CCR4; overexpression of this receptor has been reported in CTCL cases with peripheral blood involvement<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d25988e1049>Granulysin is a cytotoxic, proinflammatory, and anti-microbial agent that is expressed along with granzymes and perforin in granules of cytotoxic T cells and natural killer cells. It plays a role in innate immunity, chemotaxis, and tumor immunology and has been shown to be involved in the progression of MF<sup><a href="#ref-27">27</a></sup>. Mucin 1 C-terminal subunit controls important pathways of oncogenesis by governing cell proliferation, self-renewal, tissue invasion, and apoptosis. This heterodimeric protein protects cells against reactive oxygen species-induced death. Overexpression of this protein has been shown in CTCL cell lines<sup><a href="#ref-40">40</a></sup>. It has been suggested that the maintenance of redox balance plays a critical factor in protecting malignant cells in the CTCLs from apoptosis<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d25988e1064>Cancer stem cells have many similarities to normal stem cells, including infrequent division, high self-renewal capacity, resistance to apoptosis, and ability to maintain an undifferentiated state, overcome cellular senescence, and differentiate to all cell types. Because of their rare cell divisions, they are resistant to chemotherapeutic agents. Additionally, these cells are responsible for relapse and metastasis of tumors. The expression of embryonic stem cell genes such as Nanog homeobox (<i>NANOG</i>), <i>SRY</i> (sex determining region Y)-box (<i>SOX</i>)-<i>2</i>, and <i>OCT4</i> (<i>POU</i> class 5 homeobox [<i>POU5F</i>]<i>-1</i>) and their upstream and downstream signaling members was shown in CTCL lesions<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d25988e1096>It was proposed that the formation of blood and lymphatic vasculature is involved in the progression of CTCL. Malignant T cells produce several angiogenic factors, such as podoplanin (PDPN), lymphatic vessel hyaluronan receptor-1 (LYVE-1), vascular endothelial growth factor-C (VEGF-C), VEGF-R3, and lymphotoxin alpha (LTα), which play roles in neoangiogenesis and neo-lymphoangiogenesis. The interaction of LTα, IL-6, and VEGF has been shown to induce angiogenesis by promoting endothelial cell sprouting and tube formation<sup><a href="#ref-3">3</a></sup>.</p><p class="" id=d25988e1103>Some studies have reported an association between chronic cutaneous inflammation and subsequent development of CTCL<sup><a href="#ref-9">9</a></sup>. Chronic or professional exposure to topical chemical agents, long-lasting psoriasis, and urticaria have been proposed as risk factors<sup><a href="#ref-21">21</a></sup>. Chronically activated T lymphocytes may eventually result in the creation of an atypical T cell clone<sup><a href="#ref-9">9</a></sup>. For instance, in granulomatous MF, it appears the granulomatous inflammation may precede the lymphoma, resulting in lymphocyte proliferation through macrophage-produced IL-6<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d25988e1122>A relationship between microbial colonization/infection and MF has been suggested<sup><a href="#ref-9">9</a>,<a href="#ref-42">42</a></sup>. It has been shown that bacterial isolates containing staphylococcal enterotoxin-A (SEA) promote disease progression by inducing STAT3 activation and IL-17 expression in malignant T cells<sup><a href="#ref-42">42</a></sup>. On the other hand, during the evolutionary process of CTCLs, loss of the normal TCR repertoire results in immunosuppression and opportunistic infections leading to death<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d25988e1140>The role of viral infection in the pathogenesis of the CTCLs remains controversial. Recently, the role of retroviruses such as human T cell leukemia virus type 1 (HTLV-1) and HTLV-2 and human immunodeficiency virus and herpesvirus family members like Epstein-Barr virus, human herpesvirus 8, and cytomegalovirus have been suggested in the pathogenesis of these disorders. Viral infection may promote tumoral infiltration by inducing the production of tumor necrosis factor-alpha (TNF-α), IL-6, and IL-1a in keratinocytes. Additionally, in the skin, these organisms play the role of a stable chronic antigen, which results in a clonal proliferation of T cells, leading to CTCLs<sup><a href="#ref-4">4</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e1150>Diagnosis</h2><p class="" id=d25988e1153>The diagnosis of CTCLs is difficult at early stages because of the presence of multiple clinical presentations<sup><a href="#ref-1">1</a>,<a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup> and lack of definitive diagnostic criteria<sup><a href="#ref-1">1</a>,<a href="#ref-45">45</a></sup>. Hence, in most cases, it takes an average of 6 years from disease onset until confirmation of the diagnosis<sup><a href="#ref-1">1</a>,<a href="#ref-44">44</a></sup>.</p><p class="" id=d25988e1180>Recently, there have been advances in the accurate diagnosis of CTCLs. To diagnose the CTCLs, guidelines prepared by the National Comprehensive Cancer Network recommend biopsy of suspicious skin sites and subsequent assessment in terms of dermatopathology, immunohistochemistry, and molecular analysis (TCR gene rearrangement)<sup><a href="#ref-14">14</a></sup>. Observation and palpation of the skin are mainstays in suspecting CTCLs. Palpation of lymph nodes remains the traditional approach for staging of these disorders<sup><a href="#ref-14">14</a>,<a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. Frequently, many biopsies are required to make the definitive diagnosis, as morphologic and phenotypic manifestations of CTCLs are variable and information derived from a single biopsy can lead to misdiagnosis<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a>,<a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. Identifying malignant cells in the peripheral blood of patients with CTCL is invaluable for detecting SS in early stages and determining prognosis<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. However, blood analysis is of limited value because there is no precise marker in this analysis to detect the CTCLs in a sensitive way<sup><a href="#ref-9">9</a>,<a href="#ref-14">14</a></sup>. Lactate dehydrogenase (LDH) is a non-specific marker of tumor burden and is related to poor prognosis of CTCLs<sup><a href="#ref-9">9</a>,<a href="#ref-14">14</a></sup>. These studies provide a robust technique for assessing aberration of genes in the CTCLs<sup><a href="#ref-3">3</a>,<a href="#ref-35">35</a></sup>.</p><p class="" id=d25988e1239>Detection of a malignant T cell clone is a critical marker for definite diagnosis of CTCLs. TCRγ polymerase chain reaction (PCR) analysis detects clones of T cells in only a subset of patients, whereas the sensitivity and specificity of high-throughput TCR sequencing to detect T cell clones are higher than in TCRγ PCR. Indeed, the technique of high-throughput TCR sequencing is useful for the accurate diagnosis of all stages of CTCLs, differentiation of these disorders from benign inflammatory disorders, and determination of origin and location of malignant CTCL cells<sup><a href="#ref-14">14</a>,<a href="#ref-44">44</a></sup>. Detection of malignant cells using flow cytometry in patients with SS is an important marker for diagnosing SS<sup><a href="#ref-14">14</a>,<a href="#ref-39">39</a>,<a href="#ref-45">45</a></sup>. In advanced cases, biopsies from bone marrow and lymph nodes are important factors in diagnosis<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d25988e1263>The loss of cell surface markers such as CD26, CD27, and CD7 on malignant T cells is of value in diagnosing CTCLs. On the other hand, the overexpression of CD164 has been reported on CD4<sup>+</sup> T cells of patients with SS. In flow cytometric studies, detection of more than 20% CD164 on CD4<sup>+</sup> cells in the blood of erythrodermic cases is highly suspicious for SS. However, the sensitivity and specificity of these assays should be interpreted with caution<sup><a href="#ref-48">48</a></sup>. PCTCL-NOS is characterized by variable loss of almost all T cell antigens, CD56 positivity, and limited or absent CD30 expression<sup><a href="#ref-8">8</a></sup>. Ki67, CD34, and AgNORs are parameters of cell proliferation and angiogenesis that are well-known markers for progression of CTCLs. They are highly expressed in advanced stages of MF and are associated with shorter survival<sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d25988e1285>T-cell-specific soluble IL-2 receptor (sIL-2r)<sup><a href="#ref-9">9</a></sup> is not specific for diagnosing CTCL but is a potential marker for activity, severity, and prognosis of this disorder. The association between increased sIL-2r and either adnexal disease or advanced-stage MF has been reported. This factor has better specificity as a prognostic factor than does LDH<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d25988e1296>Recent studies have confirmed the role of the <i>TOX</i> gene as a disease marker of CTCLs. Moreover, this gene is a candidate for therapeutic targeting<sup><a href="#ref-22">22</a></sup>. Studies have suggested that <i>EPHA4</i> can be a diagnostic and prognostic marker for SS<sup><a href="#ref-13">13</a></sup>. miRNA profiling is a diagnostic marker for CTCLs. Studies have shown that minimal miRNA classifiers can determine malignant dermatoses<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d25988e1317>HTLV serology should be considered in advanced cases<sup><a href="#ref-14">14</a></sup>. Magnetic resonance imaging (MRI) or computed tomography (CT) scan<sup><a href="#ref-9">9</a></sup> is used to investigate nodal and systemic involvement<sup><a href="#ref-9">9</a>,<a href="#ref-46">46</a></sup>. Fluorine-18 fluorodeoxyglucose positron emission tomography-CT (<sup>18</sup>F-FDG PET-CT)<sup><a href="#ref-46">46</a></sup> can determine cutaneous and extracutaneous lesions in CTCLs, response to therapy, and disease recurrence. In comparison with CT scan, this modality is more sensitive and specific in detecting both cutaneous and extracutaneous involvement, particularly in determining lymph node involvement<sup><a href="#ref-46">46</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e1350>Management</h2><p class="" id=d25988e1353>There is no known cure for MF and SS<sup><a href="#ref-11">11</a></sup>; hence, therapeutic options are mostly palliative<sup><a href="#ref-1">1</a>,<a href="#ref-49">49</a></sup>, and the goals of treatment include relieving symptoms, inducing remission, and postponing progression while decreasing significant side effects caused by therapeutic modalities<sup><a href="#ref-12">12</a></sup>. Multi-drug therapeutic approaches are inappropriate for CTCLs because of the high risk of infection in patients with poor skin barrier<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d25988e1375>Before choosing the best option for treating this malignant condition, accurate staging is essential<sup><a href="#ref-1">1</a>,<a href="#ref-46">46</a>,<a href="#ref-51">51</a></sup>. Generally, therapeutic options are classified into two groups. Skin-directed therapies<sup><a href="#ref-1">1</a>,<a href="#ref-11">11</a>,<a href="#ref-45">45</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup> are the first choice for treating early stages of disease (IA to IIA) when involving less than 20% of the body surface<sup><a href="#ref-1">1</a></sup>. Systemic therapies<sup><a href="#ref-1">1</a>,<a href="#ref-11">11</a>,<a href="#ref-45">45</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup> are used for refractory cases in the early stages and cases with advanced stages (at least<i></i> IIB)<sup><a href="#ref-1">1</a>,<a href="#ref-6">6</a></sup>.</p><p class="" id=d25988e1434>Corticosteroids in topical and systemic forms are effective in treating CTCLs<sup><a href="#ref-9">9</a>,<a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. Topical corticosteroids can be employed for treating refractory cases of both early stage disease and more advanced cases. One of the problems with corticosteroid therapy is relapse of disease<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d25988e1451>Retinoids are effective in treating the CTCLs through anti-proliferative and apoptosis-inducing effects<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. Retinoic acid receptor β2 works as a tumor suppressor gene<sup><a href="#ref-56">56</a></sup>. Among topical retinoids, bexarotene, also known as Targretin, is approved by the US Food and Drug Administration (FDA) for treating stage I MF<sup><a href="#ref-1">1</a>,<a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup> and relapsed refractory CTCLs<sup><a href="#ref-58">58</a></sup>. Severe mixed hyperlipidemia with a significant decrease in high-density lipoprotein cholesterol level and central hypothyroidism are reversible, dose-dependent adverse effects of bexarotene<sup><a href="#ref-60">60</a></sup>. Tazarotene is another topical retinoid whose efficacy as a monotherapy has been shown in treating stages I to IIA CTCL<sup><a href="#ref-61">61</a></sup>. Systemic retinoids such as acitretin, isotretinoin, and bexarotene have been used successfully in the treatment of CTCLs<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d25988e1493>HDACIs, classified as anti-neoplastic agents, are novel therapeutic options for treating CTCLs<sup><a href="#ref-1">1</a>,<a href="#ref-9">9</a>,<a href="#ref-62">62</a></sup>. Their mechanisms of action are via transcription-dependent and transcription-independent ways<sup><a href="#ref-11">11</a></sup>, including (a) promoting the expression of genes that regulate cell differentiation and apoptosis, (b) inducing changes to the structural integrity of chromatin<sup><a href="#ref-1">1</a></sup>, (c) regulating miR-22 expression<sup><a href="#ref-25">25</a></sup>, and (d) increasing the production of reactive oxygen species and decreasing mitochondrial membrane<sup><a href="#ref-63">63</a></sup>. These agents preferentially destroy transformed cells over normal cells<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d25988e1527>In this therapeutic group, vorinostat<sup><a href="#ref-1">1</a>,<a href="#ref-11">11</a>,<a href="#ref-50">50</a>,<a href="#ref-58">58</a></sup> and romidepsin<sup><a href="#ref-1">1</a>,<a href="#ref-11">11</a>,<a href="#ref-50">50</a>,<a href="#ref-58">58</a>,<a href="#ref-63">63</a></sup> are FDA approved for treating progressive, persistent, or recurrent CTCLs. These agents, when given as single agents, can induce an overall response rate of 30% to 35%, but a complete response rate is seen in only 2% to 6% of cases<sup><a href="#ref-11">11</a></sup>. Entinostat, belinostat, panobinostat<sup><a href="#ref-1">1</a></sup>, AN-7<sup><a href="#ref-11">11</a></sup>, and quisinostat<sup><a href="#ref-64">64</a></sup> are other HDACIs currently under study. Generally, HDACIs are well tolerated. Fatigue, gastrointestinal discomfort, thrombocytopenia, neutropenia, anemia, and dehydration are insignificant side effects which have been reported with these agents<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d25988e1580>Imiquimod is a Toll-like receptor 7 (TLR7) agonist that is effective in treating MF. It works through inducing the production of interferon-alpha (IFN-α), TNF-α, IL-1α, IL-6, and IL-8 from plasmacytoid dendritic cells, which are seen in inflamed and malignant skin lesions. The efficacy of topical resiquimod, an imidazoquinoline with TLR7- and TLR8-stimulating activity, was shown in treating early stage CTCLs. Its effectiveness in inducing regression of untreated lesions was reported, probably mediated by enhancing systemic anti-tumor immunity. Resiquimod appears to act by recruiting and expanding benign T cell clones, increasing skin T cell effector and natural killer cell functions<sup><a href="#ref-54">54</a></sup>. </p><p class="" id=d25988e1587>Denileukin diftitox is a recombinant fusion protein<sup><a href="#ref-9">9</a>,<a href="#ref-50">50</a></sup>, composed of diphtheria toxin and IL-2, approved by the FDA for treating CTCLs<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d25988e1601>The efficacy of zanolimumab and alemtuzumab in treating the CTCLs has been reported. Zanolimumab has a lower risk of infection than does alemtuzumab<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d25988e1608>Cytokines such as IFN-α are effective in treating cases with MF and SS but can exacerbate PCTCL-NOS<sup><a href="#ref-8">8</a></sup>. IFN-α2b is still the best option as first-line systemic therapy for MF<sup><a href="#ref-51">51</a></sup>. Recombinant IL-12 is beneficial in treating CTCLs by inducing cellular immunity and cytotoxic T cell responses in the host<sup><a href="#ref-54">54</a></sup>.</p><p class="" id=d25988e1624>Chemotherapeutic agents play a role in managing CTCLs, but severe adverse effects are reported<sup><a href="#ref-11">11</a></sup>. For the most part, topical chemotherapeutic agents such as mechlorethamine (nitrogen mustard) and carmustine are successful in managing early stage disorders, but their effectiveness in treating advanced cases is doubtful<sup><a href="#ref-1">1</a>,<a href="#ref-11">11</a></sup>. Mechlorethamine was approved by the FDA for the treatment of stage Ia and Ib MF. It is an alkylating agent, which acts by inhibiting proliferating cells and affecting keratinocyte-Langerhans cell–T cell interactions. Non-melanoma skin cancers have been seen in patients who have received this agent in combination with phototherapy, radiation, and immunosuppressive chemotherapy<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d25988e1642>Other systemic chemotherapeutic agents that have been used to treat CTCLs include methotrexate, chlorambucil, gemcitabine, and pegylated doxorubicin<sup><a href="#ref-9">9</a></sup>. Pralatrexate is a methotrexate analog approved by the FDA for treating relapsed or refractory CTCLs<sup><a href="#ref-50">50</a></sup>. Studies have shown variable efficacy for cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of advanced cases of CTCLs<sup><a href="#ref-9">9</a>,<a href="#ref-50">50</a></sup>.</p><p class="" id=d25988e1660>Psoralen plus ultraviolet A (PUVA), ultraviolet B (UVB)<sup><a href="#ref-9">9</a></sup>, UVA1, and excimer laser<sup><a href="#ref-65">65</a></sup> are among the most common treatments used for achieving remission or avoidance of progression in MF. In comparison with PUVA, UVB is less effective at treating infiltrated lesions; additionally, remission duration is shorter with UVB<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d25988e1675>Radiotherapy is an effective skin-directed therapy for the treatment of CTCLs<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. Lymphocytes are sensitive to radiation therapy. In more advanced cases, radiation therapy to local lesions or to the entire skin can control disease. For cases with a single lesion, this modality can be curative<sup><a href="#ref-66">66</a></sup>.</p><p class="" id=d25988e1689>Electron beam radiation therapy is effective in treating CTCLs<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a>,<a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup> in stages I to III<sup><a href="#ref-50">50</a></sup>. Whole-body total skin electron beam is an appropriate modality for more advanced cases<sup><a href="#ref-1">1</a>,<a href="#ref-50">50</a></sup>. Complete response rate is lower in tumor-stage disease in comparison with plaque-stage cases (36% versus 98.3%)<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d25988e1720>Conventional photodynamic therapy with aminolevulinic acid (ALA-PDT) is effective in a subset of CTCLs because it acts through apoptosis while the expression of death receptors like FAS in malignant T cells is low. The combination of methotrexate with ALA-PDT enhances the efficacy of photodynamic therapy through upregulating FAS by inhibiting the methylation of its promoter<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d25988e1728>Extracorporeal photopheresis is an immunomodulating method resulting in the expansion of the peripheral blood dendritic cell population and enhancement of the TH1 immune response<sup><a href="#ref-71">71</a></sup>. It is an appropriate modality for treating refractory, early stage MF<sup><a href="#ref-71">71</a></sup> and SS<sup><a href="#ref-50">50</a>,<a href="#ref-71">71</a></sup>. With this modality, a partial response rate of 30% to 80% and a complete remission rate of 14% to 25% are estimated<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d25988e1750>Allogeneic hematopoietic stem cell transplantations are used for treating advanced stages of MF, SS<sup><a href="#ref-7">7</a>,<a href="#ref-53">53</a>,<a href="#ref-54">54</a>,<a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>, and PCTCL-NOS<sup><a href="#ref-8">8</a></sup>. Studies have shown that this therapeutic option is appropriate for young patients<sup><a href="#ref-7">7</a>,<a href="#ref-50">50</a>,<a href="#ref-72">72</a></sup> with relapsing diseases which progress in spite of several lines of chemotherapy<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d25988e1787>The efficacy of some agents, including tazarotene, lenalidomide, forodesine (BCX-1777), synthetic oligonucleotides, temozolomide, C-beta kinase inhibitor<sup><a href="#ref-50">50</a></sup>, mucin 1 C inhibitors<sup><a href="#ref-40">40</a></sup>, everolimus<sup><a href="#ref-74">74</a></sup>, PD1/PD-L1 inhibitors<sup><a href="#ref-75">75</a></sup>, brentuximab vedotin, and mogamulizumab, is under investigation<sup><a href="#ref-62">62</a>,<a href="#ref-75">75</a></sup>.</p><p class="" id=d25988e1813>As mucin 1 is overexpressed in cells of CTCLs, therapies targeting mucin 1 are effective in treating CTCLs. Theoretically, mucin 1 C inhibitors (such as GO-203), which increase the level of reactive oxygen species and lead to oxidative-stress-induced late apoptosis/necrosis, can be an effective treatment<sup><a href="#ref-40">40</a></sup>. Everolimus, which targets the mammalian target of rapamycin (mTOR) pathway, appears to be effective in treating T cell lymphoma by inhibiting malignant T cell proliferation<sup><a href="#ref-74">74</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e1827>Prognosis</h2><p class="" id=d25988e1830>CTCLs are lifelong disorders that recur after discontinuation of therapy, even in cases that do not progress<sup><a href="#ref-54">54</a></sup>. In spite of the introduction of several therapeutic options for CTCLs, as they progress and become refractory to treatment, the malignant cells have the propensity to infiltrate lymph nodes and peripheral blood vessels, resulting in debilitating states. Progression to tumor stage where the neoplastic cells spread to the lymph nodes and internal organs has been reported in less than 5% of cases with CTCL<sup><a href="#ref-1">1</a></sup>. In <a href="#T3">Table 3</a>, prognostic factors for CTCLs are listed<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a>,<a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-12">12</a>,<a href="#ref-14">14</a>,<a href="#ref-22">22</a>,<a href="#ref-27">27</a>,<a href="#ref-39">39</a>,<a href="#ref-40">40</a>,<a href="#ref-46">46</a>,<a href="#ref-51">51</a>,<a href="#ref-52">52</a>,<a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Prognostic factors in cutaneous T cell lymphoma cases.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25988e1903 class=n-a></a><tbody><a name=d25988e1905 class=n-a></a><tr><a name=d25988e1907 class=n-a></a><td colspan=1 rowspan=1><a name=d25988e1909 class=n-a></a> <b>Clinical factors</b> <br class=br>Age<sup><a href="#ref-5">5</a>,<a href="#ref-8">8</a>,<a href="#ref-52">52</a>,<a href="#ref-77">77</a></sup> <br class=br>Sex<sup><a href="#ref-52">52</a></sup> <br class=br>Staging<sup><a href="#ref-47">47</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup> <br class=br>Extent and type of cutaneous involvement<sup><a href="#ref-1">1</a>,<a href="#ref-9">9</a>,<a href="#ref-47">47</a>,<a href="#ref-53">53</a></sup> <br class=br>Presence of extracutaneous involvement<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a>,<a href="#ref-46">46</a>,<a href="#ref-52">52</a></sup> such as<br class=br>blood<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>, bone marrow<sup><a href="#ref-8">8</a></sup>, and adnexal<sup><a href="#ref-9">9</a></sup> involvement<br class=br>Disease progression<sup><a href="#ref-1">1</a></sup> <br class=br>Old refractoriness to successive treatment protocols<sup><a href="#ref-5">5</a></sup> </td></tr><tr><a name=d25988e2017 class=n-a></a><td colspan=1 rowspan=1><a name=d25988e2019 class=n-a></a> <b>Laboratory factors</b> <br class=br>Proliferation index<sup><a href="#ref-52">52</a></sup> <br class=br>Folliculotropism<sup><a href="#ref-52">52</a></sup> <br class=br>Presence of Sézary cells<sup><a href="#ref-5">5</a>,<a href="#ref-40">40</a></sup> <br class=br>Large cell transformation in histology<sup><a href="#ref-14">14</a>,<a href="#ref-41">41</a>,<a href="#ref-52">52</a></sup> <br class=br>White blood cell/lymphocyte count<sup><a href="#ref-52">52</a></sup> <br class=br>Loss of T cell receptor repertoire<sup><a href="#ref-39">39</a></sup> <br class=br>Increased level of soluble interleukin-2 receptor at initial<br class=br>diagnosis<sup><a href="#ref-9">9</a></sup><br class=br>Normal or high levels of lactate dehydrogenase<sup><a href="#ref-8">8</a>,<a href="#ref-52">52</a>,<a href="#ref-77">77</a></sup> <br class=br>CD30 expression of less than 10%<sup><a href="#ref-52">52</a>,<a href="#ref-77">77</a></sup> <br class=br>Overexpression of TOX<sup><a href="#ref-22">22</a></sup> <br class=br>Expression of proliferation markers Ki-67, MCM-3, and MCM-7<sup><a href="#ref-78">78</a></sup> <br class=br>MicroRNA profiling<sup><a href="#ref-25">25</a></sup> <br class=br>Granulysin expression<sup><a href="#ref-27">27</a></sup> <br class=br>Presence of FOXP3<sup>+</sup> regulatory T cells<sup><a href="#ref-27">27</a></sup> <br class=br>EPHA4 expression<sup><a href="#ref-13">13</a></sup> </td></tr></tbody></table></div><p class="" id=d25988e2146>In CTCL cases with visceral involvement, skin lesions are severe and the risk of skin infection is high. On the other hand, autopsy studies have shown that between 70% and 90% of patients with MF die with visceral involvement<sup><a href="#ref-5">5</a></sup>. Moreover, primary CTCLs have distinctive clinical behavior in comparison with systemic lymphomas with skin involvement<sup><a href="#ref-78">78</a></sup>.</p><p class="" id=d25988e2157>At early stages, there is no significant difference between the life expectancy of patients with CTCL and that of healthy people<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a></sup>, whereas in more progressed cases, life expectancy decreases to 3.2 to 9.9 years<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d25988e2172>Patients with MF have a chronic course lasting from years to decades; many of them die from unrelated disorders, whereas about 25% of them die of lymphoma<sup><a href="#ref-9">9</a></sup>. Immunosuppression and opportunistic infections are the most common causes of disease-related death<sup><a href="#ref-11">11</a></sup>. The prognosis of SS is poor. Its median survival rate is from 2 to 4 years<sup><a href="#ref-1">1</a></sup>, and its 5-year survival rate is approximately 18% to 20%<sup><a href="#ref-7">7</a></sup>. In PCTCL-NOSs, the 5-year survival rate is less than 20%<sup><a href="#ref-8">8</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25988e2199>Conclusion</h2><p class="" id=d25988e2202>Although there are many studies regarding the pathogenesis and management of the CTCLs, many questions about this complicated group of diseases remain unanswered.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d25988e1 class=n-a></a><h2 class=main-title id=d26264>Competing interests</h2><p class=metadata-entry><a name=d25988e96 class=n-a></a><p id=d25988e98> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d25988e1 class=n-a></a><h2 class=main-title id=d26266>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d25988e2209 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d26526>References</h2><div class="section ref-list"><a name=d25988e2209 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d25988e2216 class=n-a></a>Rodd AL, Ververis K, Karagiannis TC: Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. <i>Lymphoma.</i> 2012; <b>2012</b>: 1–10, 290685. <a target=xrefwindow id=d25988e2224 href="http://dx.doi.org/10.1155/2012/290685">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725471409"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2233 class=n-a></a>Litvinov IV, Netchiporouk E, Cordeiro B, <i> et al.</i>: Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. <i>Oncoimmunology.</i> 2014; <b>3</b>(11): e970025. <a target=xrefwindow id=d25988e2244 href="http://www.ncbi.nlm.nih.gov/pubmed/25941598">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2247 href="http://dx.doi.org/10.4161/21624011.2014.970025">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2251 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4368148">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725471409">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725451970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2264 class=n-a></a>Lauenborg B, Christensen L, Ralfkiaer U, <i> et al.</i>: Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma. <i>Oncotarget.</i> 2015; <b>6</b>(17): 15235–49. <a target=xrefwindow id=d25988e2275 href="http://www.ncbi.nlm.nih.gov/pubmed/25915535">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2278 href="http://dx.doi.org/10.18632/oncotarget.3837">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2282 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4558148">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725451970">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726568333"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2295 class=n-a></a>Nahidi Y, Meibodi NT, Ghazvini K, <i> et al.</i>: Evaluation of the Association Between Epstein-Barr Virus and Mycosis Fungoides. <i>Indian J Dermatol.</i> 2015; <b>60</b>(3): 321. <a target=xrefwindow id=d25988e2306 href="http://www.ncbi.nlm.nih.gov/pubmed/26120176">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2309 href="http://dx.doi.org/10.4103/0019-5154.156423">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4458961">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726568333">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d25988e2326 class=n-a></a>Gómez Venegas ÁA, Vargas Rubio RD: Unusual involvement in mycosis fungoides: Duodenal papilla. <i>Rev Esp Enferm Dig.</i> 2015. <a target=xrefwindow id=d25988e2331 href="http://www.ncbi.nlm.nih.gov/pubmed/26652167">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2334 href="http://dx.doi.org/10.17235/reed.2015.3831/2015">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d25988e2344 class=n-a></a>Devata S, Wilcox RA: Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. <i>Am J Clin Dermatol.</i> 2016; <b>17</b>(3): 225–37. <a target=xrefwindow id=d25988e2352 href="http://www.ncbi.nlm.nih.gov/pubmed/26923912">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2355 href="http://dx.doi.org/10.1007/s40257-016-0177-5">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d25988e2364 class=n-a></a>Väkevä L, Niittyvuopio R, Leppä S, <i> et al.</i>: Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma. <i>Acta Derm Venereol.</i> 2016. <a target=xrefwindow id=d25988e2372 href="http://www.ncbi.nlm.nih.gov/pubmed/26864630">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2375 href="http://dx.doi.org/10.2340/00015555-2362">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d25988e2384 class=n-a></a>Aderhold K, Carpenter L, Brown K, <i> et al.</i>: Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma. <i>Case Rep Oncol Med.</i> 2015; <b>2015</b>: 429068. <a target=xrefwindow id=d25988e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/26380134">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2398 href="http://dx.doi.org/10.1155/2015/429068">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2402 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4563086">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d25988e2411 class=n-a></a>Eklund Y, Aronsson A, Schmidtchen A, <i> et al.</i>: Mycosis Fungoides: A Retrospective Study of 44 Swedish Cases. <i>Acta Derm Venereol.</i> 2016; <b>96</b>(5): 669–73. <a target=xrefwindow id=d25988e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/26778803">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2425 href="http://dx.doi.org/10.2340/00015555-2337">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d25988e2434 class=n-a></a>Maj J, Jankowska-Konsur AM, Hałoń A, <i> et al.</i>: Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. <i>Postepy Dermatol Alergol.</i> 2015; <b>32</b>(6): 437–42. <a target=xrefwindow id=d25988e2445 href="http://www.ncbi.nlm.nih.gov/pubmed/26755907">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2448 href="http://dx.doi.org/10.5114/pdia.2015.48034">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2452 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4697019">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d25988e2461 class=n-a></a>Moyal L, Feldbaum N, Goldfeiz N, <i> et al.</i>: The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. <i>PLoS One.</i> 2016; <b>11</b>(1): e0146115. <a target=xrefwindow id=d25988e2472 href="http://www.ncbi.nlm.nih.gov/pubmed/26752418">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2475 href="http://dx.doi.org/10.1371/journal.pone.0146115">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2479 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4709199">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725658437"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2489 class=n-a></a>Choi J, Goh G, Walradt T, <i> et al.</i>: Genomic landscape of cutaneous T cell lymphoma. <i>Nat Genet.</i> 2015; <b>47</b>(9): 1011–9. <a target=xrefwindow id=d25988e2500 href="http://www.ncbi.nlm.nih.gov/pubmed/26192916">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2503 href="http://dx.doi.org/10.1038/ng.3356">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4552614">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725658437">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d25988e2520 class=n-a></a>Hameetman L, van der Fits L, Zoutman WH, <i> et al.</i>: EPHA4 is overexpressed but not functionally active in Sézary syndrome. <i>Oncotarget.</i> 2015; <b>6</b>(31): 31868–76. <a target=xrefwindow id=d25988e2531 href="http://www.ncbi.nlm.nih.gov/pubmed/26376612">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2534 href="http://dx.doi.org/10.18632/oncotarget.5573">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4741646">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d25988e2547 class=n-a></a>Benjamin Chase A, Markel K, Tawa MC: Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. <i>Clin J Oncol Nurs.</i> 2015; <b>19</b>(6): E131–9. <a target=xrefwindow id=d25988e2555 href="http://www.ncbi.nlm.nih.gov/pubmed/26583648">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2558 href="http://dx.doi.org/10.1188/15.CJON.E131-E139">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d25988e2567 class=n-a></a>Foo SH, Shah F, Chaganti S, <i> et al.</i>: Unmasking mycosis fungoides/Sézary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course. <i>Br J Dermatol.</i> 2016; <b>174</b>(4): 901–4. <a target=xrefwindow id=d25988e2578 href="http://www.ncbi.nlm.nih.gov/pubmed/26479768">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2581 href="http://dx.doi.org/10.1111/bjd.14238">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d25988e2590 class=n-a></a>Pankratov O, Gradova S, Tarasevich S, <i> et al.</i>: Poikilodermatous mycosis fungoides: clinical and histopathological analysis of a case and literature review. <i>Acta Dermatovenerol Alp Pannonica Adriat.</i> 2015; <b>24</b>(2): 37–41. <a target=xrefwindow id=d25988e2601 href="http://www.ncbi.nlm.nih.gov/pubmed/26086166">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2604 href="http://dx.doi.org/10.15570/actaapa.2015.10">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d25988e2613 class=n-a></a>LeBlanc RE, Tavallaee M, Kim YH, <i> et al.</i>: Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis. <i>Am J Surg Pathol.</i> 2016; <b>40</b>(6): 745–54. <a target=xrefwindow id=d25988e2624 href="http://www.ncbi.nlm.nih.gov/pubmed/26796503">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2627 href="http://dx.doi.org/10.1097/PAS.0000000000000596">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d25988e2637 class=n-a></a>Smoller BR, Bishop K, Glusac E, <i> et al.</i>: Reassessment of histologic parameters in the diagnosis of mycosis fungoides. <i>Am J Surg Pathol.</i> 1995; <b>19</b>(12): 1423–30. <a target=xrefwindow id=d25988e2648 href="http://www.ncbi.nlm.nih.gov/pubmed/7503364">PubMed Abstract </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d25988e2657 class=n-a></a>Kash N, Massone C, Fink-Puches R, <i> et al.</i>: Phenotypic Variation in Different Lesions of Mycosis Fungoides Biopsied Within a Short Period of Time From the Same Patient. <i>Am J Dermatopathol.</i> 2016; <b>38</b>(7): 541–5. <a target=xrefwindow id=d25988e2668 href="http://www.ncbi.nlm.nih.gov/pubmed/26885605">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2671 href="http://dx.doi.org/10.1097/DAD.0000000000000493">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d25988e2680 class=n-a></a>Smoller BR: Mycosis fungoides: what do/do not we know? <i>J Cutan Pathol.</i> 2008; <b>35</b>(Suppl 2): 35–9. <a target=xrefwindow id=d25988e2688 href="http://www.ncbi.nlm.nih.gov/pubmed/18976417">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2691 href="http://dx.doi.org/10.1111/j.1600-0560.2008.01120.x">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d25988e2700 class=n-a></a>Lebas E, Libon F, Nikkels AF: Koebner Phenomenon and Mycosis Fungoides. <i>Case Rep Dermatol.</i> 2015; <b>7</b>(3): 287–91. <a target=xrefwindow id=d25988e2708 href="http://www.ncbi.nlm.nih.gov/pubmed/26557075">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2711 href="http://dx.doi.org/10.1159/000440856">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4637793">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725929342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2723 class=n-a></a>Dulmage BO, Akilov O, Vu JR, <i> et al.</i>: Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. <i>Oncotarget.</i> 2015. <a target=xrefwindow id=d25988e2731 href="http://www.ncbi.nlm.nih.gov/pubmed/26556870">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2734 href="http://dx.doi.org/10.18632/oncotarget.5742">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725929342">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d25988e2747 class=n-a></a>Wang L, Ni X, Covington KR, <i> et al.</i>: Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. <i>Nat Genet.</i> 2015; <b>47</b>(12): 1426–34. <a target=xrefwindow id=d25988e2758 href="http://www.ncbi.nlm.nih.gov/pubmed/26551670">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2761 href="http://dx.doi.org/10.1038/ng.3444">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4829974">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d25988e2775 class=n-a></a>da Silva Almeida AC, Abate F, Khiabanian H, <i> et al.</i>: The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. <i>Nat Genet.</i> 2015; <b>47</b>(12): 1465–70. <a target=xrefwindow id=d25988e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/26551667">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2789 href="http://dx.doi.org/10.1038/ng.3442">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2793 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4878831">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725700859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2802 class=n-a></a>Sibbesen NA, Kopp KL, Litvinov IV, <i> et al.</i>: Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. <i>Oncotarget.</i> 2015; <b>6</b>(24): 20555–69. <a target=xrefwindow id=d25988e2813 href="http://www.ncbi.nlm.nih.gov/pubmed/26244872">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2816 href="http://dx.doi.org/10.18632/oncotarget.4111">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4653025">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725700859">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d25988e2833 class=n-a></a>Woollard WJ, Kalaivani NP, Jones CL, <i> et al.</i>: Independent Loss of Methylthioadenosine Phosphorylase <i>(MTAP)</i> in Primary Cutaneous T-Cell Lymphoma. <i>J Invest Dermatol.</i> 2016; <b>136</b>(6): 1238–46. <a target=xrefwindow id=d25988e2847 href="http://www.ncbi.nlm.nih.gov/pubmed/26872600">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2851 href="http://dx.doi.org/10.1016/j.jid.2016.01.028">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725686557"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2860 class=n-a></a>Shareef MM, Elgarhy LH, Wasfy Rel-S: Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome. <i>Asian Pac J Cancer Prev.</i> 2015; <b>16</b>(13): 5359–64. <a target=xrefwindow id=d25988e2868 href="http://www.ncbi.nlm.nih.gov/pubmed/26225678">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2871 href="http://dx.doi.org/10.7314/APJCP.2015.16.13.5359">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725686557">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d25988e2884 class=n-a></a>McGirt LY, Jia P, Baerenwald DA, <i> et al.</i>: Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. <i>Blood.</i> 2015; <b>126</b>(4): 508–19. <a target=xrefwindow id=d25988e2895 href="http://www.ncbi.nlm.nih.gov/pubmed/26082451">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2898 href="http://dx.doi.org/10.1182/blood-2014-11-611194">Publisher Full Text </a> | <a target=xrefwindow id=d25988e2902 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4513251">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d25988e2911 class=n-a></a>Jankowska-Konsur A, Kobierzycki C, Reich A, <i> et al.</i>: Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides. <i>Anticancer Res.</i> 2016; <b>36</b>(1): 189–97. <a target=xrefwindow id=d25988e2922 href="http://www.ncbi.nlm.nih.gov/pubmed/26722043">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725708573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e2932 class=n-a></a>Ungewickell A, Bhaduri A, Rios E, <i> et al.</i>: Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. <i>Nat Genet.</i> 2015; <b>47</b>(8): 1056–60. <a target=xrefwindow id=d25988e2943 href="http://www.ncbi.nlm.nih.gov/pubmed/26258847">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2946 href="http://dx.doi.org/10.1038/ng.3370">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725708573">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d25988e2959 class=n-a></a>Gallardo F, Sandoval J, Díaz-Lagares A, <i> et al.</i>: Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides. <i>J Invest Dermatol.</i> 2015; <b>135</b>(12): 3144–52. <a target=xrefwindow id=d25988e2970 href="http://www.ncbi.nlm.nih.gov/pubmed/26302069">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2973 href="http://dx.doi.org/10.1038/jid.2015.328">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d25988e2982 class=n-a></a>Tensen CP: <i>PLCG1</i> Gene Mutations in Cutaneous T-Cell Lymphomas Revisited. <i>J Invest Dermatol.</i> 2015; <b>135</b>(9): 2153–4. <a target=xrefwindow id=d25988e2993 href="http://www.ncbi.nlm.nih.gov/pubmed/26269406">PubMed Abstract </a> | <a target=xrefwindow id=d25988e2996 href="http://dx.doi.org/10.1038/jid.2015.221">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d25988e3005 class=n-a></a>Kitadate A, Ikeda S, Teshima K, <i> et al.</i>: MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas. <i>Oncogene.</i> 2016; <b>35</b>(28): 3692–704. <a target=xrefwindow id=d25988e3016 href="http://www.ncbi.nlm.nih.gov/pubmed/26640145">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3019 href="http://dx.doi.org/10.1038/onc.2015.435">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d25988e3028 class=n-a></a>Katona TM, Smoller BR, Webb AL, <i> et al.</i>: Expression of PTEN in mycosis fungoides and correlation with loss of heterozygosity. <i>Am J Dermatopathol.</i> 2013; <b>35</b>(5): 555–60. <a target=xrefwindow id=d25988e3039 href="http://www.ncbi.nlm.nih.gov/pubmed/23715078">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3042 href="http://dx.doi.org/10.1097/DAD.0b013e318276cc68">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d25988e3051 class=n-a></a>Katona TM, O'Malley DP, Cheng L, <i> et al.</i>: Loss of heterozygosity analysis identifies genetic abnormalities in mycosis fungoides and specific loci associated with disease progression. <i>Am J Surg Pathol.</i> 2007; <b>31</b>(10): 1552–6. <a target=xrefwindow id=d25988e3062 href="http://www.ncbi.nlm.nih.gov/pubmed/17895757">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3065 href="http://dx.doi.org/10.1097/PAS.0b013e3180408d76">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d25988e3075 class=n-a></a>Kabasawa M, Sugaya M, Oka T, <i> et al.</i>: Decreased interleukin-21 expression in skin and blood in advanced mycosis fungoides. <i>J Dermatol.</i> 2016; <b>43</b>(7): 819–22. <a target=xrefwindow id=d25988e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/26825047">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3089 href="http://dx.doi.org/10.1111/1346-8138.13278">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d25988e3098 class=n-a></a>Vieyra-Garcia PA, Wei T, Naym DG, <i> et al.</i>: STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides. <i>Clin Cancer Res.</i> 2016; <b>22</b>(13): 3328–39. <a target=xrefwindow id=d25988e3109 href="http://www.ncbi.nlm.nih.gov/pubmed/26851186">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3112 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-1784">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726087201"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3121 class=n-a></a>Ikeda S, Kitadate A, Ito M, <i> et al.</i>: Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. <i>Oncotarget.</i> 2016; <b>7</b>(12): 13563–74. <a target=xrefwindow id=d25988e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/26789110">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3135 href="http://dx.doi.org/10.18632/oncotarget.6916">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3139 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4924661">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726087201">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725902147"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3152 class=n-a></a>Guenova E, Ignatova D, Chang YT, <i> et al.</i>: Expression of CD164 on Malignant T cells in Sézary Syndrome. <i>Acta Derm Venereol.</i> 2016; <b>96</b>(4): 464–7. <a target=xrefwindow id=d25988e3163 href="http://www.ncbi.nlm.nih.gov/pubmed/26524186">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3166 href="http://dx.doi.org/10.2340/00015555-2264">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725902147">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725538149"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3179 class=n-a></a>Jain S, Stroopinsky D, Yin L, <i> et al.</i>: Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood.</i> 2015; <b>126</b>(3): 354–62. <a target=xrefwindow id=d25988e3190 href="http://www.ncbi.nlm.nih.gov/pubmed/26048911">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3193 href="http://dx.doi.org/10.1182/blood-2015-02-628149">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4504948">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725538149">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d25988e3210 class=n-a></a>Pousa CM, Nery NS, Mann D, <i> et al.</i>: Granulomatous mycosis fungoides--a diagnostic challenge. <i>An Bras Dermatol.</i> 2015; <b>90</b>(4): 554–6. <a target=xrefwindow id=d25988e3221 href="http://www.ncbi.nlm.nih.gov/pubmed/26375225">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3224 href="http://dx.doi.org/10.1590/abd1806-4841.20153460">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3228 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4560545">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726061197"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3238 class=n-a></a>Willerslev-Olsen A, Krejsgaard T, Lindahl LM, <i> et al.</i>: Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. <i>Blood.</i> 2016; <b>127</b>(10): 1287–96. <a target=xrefwindow id=d25988e3249 href="http://www.ncbi.nlm.nih.gov/pubmed/26738536">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3252 href="http://dx.doi.org/10.1182/blood-2015-08-662353">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3256 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4786838">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726061197">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d25988e3269 class=n-a></a>Sidiropoulos KG, Martinez-Escala ME, Yelamos O, <i> et al.</i>: Primary cutaneous T-cell lymphomas: a review. <i>J Clin Pathol.</i> 2015; <b>68</b>(12): 1003–10. <a target=xrefwindow id=d25988e3280 href="http://www.ncbi.nlm.nih.gov/pubmed/26602417">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3283 href="http://dx.doi.org/10.1136/jclinpath-2015-203133">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725839869"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3292 class=n-a></a>Kirsch IR, Watanabe R, O'Malley JT, <i> et al.</i>: TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. <i>Sci Transl Med.</i> 2015; <b>7</b>(308): 308ra158. <a target=xrefwindow id=d25988e3303 href="http://www.ncbi.nlm.nih.gov/pubmed/26446955">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3306 href="http://dx.doi.org/10.1126/scitranslmed.aaa9122">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3310 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4765389">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725839869">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d25988e3323 class=n-a></a>Hughes CF, Newland K, McCormack C, <i> et al.</i>: Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers. <i>Australas J Dermatol.</i> 2015. <a target=xrefwindow id=d25988e3331 href="http://www.ncbi.nlm.nih.gov/pubmed/25988337">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3334 href="http://dx.doi.org/10.1111/ajd.12349">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726568336"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3343 class=n-a></a>Alanteri E, Usmani S, Marafi F, <i> et al.</i>: The role of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with mycosis fungoides. <i>Indian J Nucl Med.</i> 2015; <b>30</b>(3): 199–203. <a target=xrefwindow id=d25988e3354 href="http://www.ncbi.nlm.nih.gov/pubmed/26170561">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3357 href="http://dx.doi.org/10.4103/0972-3919.158527">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3361 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4479907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726568336">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d25988e3374 class=n-a></a>Gibson JF, Huang J, Liu KJ, <i> et al.</i>: Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. <i>J Am Acad Dermatol.</i> 2016; <b>74</b>(5): 870–7. <a target=xrefwindow id=d25988e3385 href="http://www.ncbi.nlm.nih.gov/pubmed/26874819">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3388 href="http://dx.doi.org/10.1016/j.jaad.2015.12.018">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4835257">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d25988e3402 class=n-a></a>Aggarwal S, Topaloglu H, Kumar S: Systematic Review Of Burden Of Cutaneous T-Cell Lymphoma. <i>Value Health.</i> 2015; <b>18</b>(7): A438. <a target=xrefwindow id=d25988e3410 href="http://www.ncbi.nlm.nih.gov/pubmed/26532464">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3413 href="http://dx.doi.org/10.1016/j.jval.2015.09.1065">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d25988e3422 class=n-a></a>Ahmed SK, Grams MP, Locher SE, <i> et al.</i>: Adaptation of the Stanford technique for treatment of bulky cutaneous T-cell lymphoma of the head. <i>Pract Radiat Oncol.</i> 2016; <b>6</b>(3): 183–6. <a target=xrefwindow id=d25988e3433 href="http://www.ncbi.nlm.nih.gov/pubmed/26712465">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3436 href="http://dx.doi.org/10.1016/j.prro.2015.10.021">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d25988e3445 class=n-a></a>Chmielowska E, Studziński M, Giebel S, <i> et al.</i>: Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. <i>Postepy Dermatol Alergol.</i> 2015; <b>32</b>(2): 67–72. <a target=xrefwindow id=d25988e3456 href="http://www.ncbi.nlm.nih.gov/pubmed/26015774">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3459 href="http://dx.doi.org/10.5114/pdia.2014.40941">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3463 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4436229">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d25988e3472 class=n-a></a>Scarisbrick JJ, Prince HM, Vermeer MH, <i> et al.</i>: Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>J Clin Oncol.</i> 2015; <b>33</b>(32): 3766–73. <a target=xrefwindow id=d25988e3483 href="http://www.ncbi.nlm.nih.gov/pubmed/26438120">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3486 href="http://dx.doi.org/10.1200/JCO.2015.61.7142">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d25988e3495 class=n-a></a>Wilcox RA: Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. <i>Am J Hematol.</i> 2016; <b>91</b>(1): 151–65. <a target=xrefwindow id=d25988e3503 href="http://www.ncbi.nlm.nih.gov/pubmed/26607183">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3506 href="http://dx.doi.org/10.1002/ajh.24233">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4715621">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d25988e3518 class=n-a></a>Virmani P, Zain J, Rosen ST, <i> et al.</i>: Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. <i>Dermatol Clin.</i> 2015; <b>33</b>(4): 807–18. <a target=xrefwindow id=d25988e3529 href="http://www.ncbi.nlm.nih.gov/pubmed/26433851">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3532 href="http://dx.doi.org/10.1016/j.det.2015.05.014">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725687268"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3542 class=n-a></a>Rook AH, Gelfand JM, Wysocka M, <i> et al.</i>: Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. <i>Blood.</i> 2015; <b>126</b>(12): 1452–61. <a target=xrefwindow id=d25988e3553 href="http://www.ncbi.nlm.nih.gov/pubmed/26228486">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3556 href="http://dx.doi.org/10.1182/blood-2015-02-630335">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4573868">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725687268">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d25988e3573 class=n-a></a>Nguyen CV, Bohjanen KA: Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. <i>Dermatol Clin.</i> 2015; <b>33</b>(4): 683–96. <a target=xrefwindow id=d25988e3581 href="http://www.ncbi.nlm.nih.gov/pubmed/26433841">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3584 href="http://dx.doi.org/10.1016/j.det.2015.05.004">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d25988e3593 class=n-a></a>Kato Y, Egusa C, Maeda T, <i> et al.</i>: Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. <i>J Dermatol Sci.</i> 2016; <b>81</b>(1): 17–25. <a target=xrefwindow id=d25988e3604 href="http://www.ncbi.nlm.nih.gov/pubmed/26596218">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3607 href="http://dx.doi.org/10.1016/j.jdermsci.2015.10.016">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d25988e3616 class=n-a></a>Huen AO, Kim EJ: The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. <i>Dermatol Clin.</i> 2015; <b>33</b>(4): 715–29. <a target=xrefwindow id=d25988e3624 href="http://www.ncbi.nlm.nih.gov/pubmed/26433844">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3627 href="http://dx.doi.org/10.1016/j.det.2015.05.007">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d25988e3636 class=n-a></a>Zinzani PL, Bonthapally V, Huebner D, <i> et al.</i>: Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Crit Rev Oncol Hematol.</i> 2016; <b>99</b>: 228–40. <a target=xrefwindow id=d25988e3647 href="http://www.ncbi.nlm.nih.gov/pubmed/26811014">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3650 href="http://dx.doi.org/10.1016/j.critrevonc.2015.12.018">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d25988e3659 class=n-a></a>Marciano DP, Kuruvilla DS, Pascal BD, <i> et al.</i>: Identification of Bexarotene as a PPARγ Antagonist with HDX. <i>PPAR Res.</i> 2015; <b>2015</b>: 254560. <a target=xrefwindow id=d25988e3670 href="http://www.ncbi.nlm.nih.gov/pubmed/26451138">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3673 href="http://dx.doi.org/10.1155/2015/254560">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3677 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4586960">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d25988e3687 class=n-a></a>Rodriguez Suarez S, Pamies Andreu E, Muñiz Grijalvo O, <i> et al.</i>: [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. <i>Med Clin (Barc).</i> 2016; <b>146</b>(3): 117–20. <a target=xrefwindow id=d25988e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/26688184">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3701 href="http://dx.doi.org/10.1016/j.medcli.2015.07.017">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726568337"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3710 class=n-a></a>Besner Morin C, Roberge D, Turchin I, <i> et al.</i>: Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma. <i>J Cutan Med Surg.</i> 2016; <b>20</b>(3): 244–8. <a target=xrefwindow id=d25988e3721 href="http://www.ncbi.nlm.nih.gov/pubmed/26742957">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3724 href="http://dx.doi.org/10.1177/1203475415626686">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726568337">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d25988e3737 class=n-a></a>Chung CG, Poligone B: Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy. <i>Curr Hematol Malig Rep.</i> 2015; <b>10</b>(4): 468–76. <a target=xrefwindow id=d25988e3745 href="http://www.ncbi.nlm.nih.gov/pubmed/26626770">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3748 href="http://dx.doi.org/10.1007/s11899-015-0293-y">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d25988e3757 class=n-a></a>Valdez BC, Brammer JE, Li Y, <i> et al.</i>: Romidepsin targets multiple survival signaling pathways in malignant T cells. <i>Blood Cancer J.</i> 2015; <b>5</b>: e357. <a target=xrefwindow id=d25988e3768 href="http://www.ncbi.nlm.nih.gov/pubmed/26473529">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3771 href="http://dx.doi.org/10.1038/bcj.2015.83">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4635192">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d25988e3784 class=n-a></a>Child F, Ortiz-Romero PL, Alvarez R, <i> et al.</i>: Phase II Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Mycosis Fungoides/Sézary Syndrome. <i>Br J Dermatol.</i> 2016. <a target=xrefwindow id=d25988e3792 href="http://www.ncbi.nlm.nih.gov/pubmed/26836950">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3795 href="http://dx.doi.org/10.1111/bjd.14427">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d25988e3804 class=n-a></a>Olsen EA, Hodak E, Anderson T, <i> et al.</i>: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. <i>J Am Acad Dermatol.</i> 2016; <b>74</b>(1): 27–58. <a target=xrefwindow id=d25988e3815 href="http://www.ncbi.nlm.nih.gov/pubmed/26547257">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3818 href="http://dx.doi.org/10.1016/j.jaad.2015.09.033">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726568338"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3828 class=n-a></a>Tandberg DJ, Craciunescu O, Kelsey CR: Radiation Therapy for Cutaneous T-Cell Lymphomas. <i>Dermatol Clin.</i> 2015; <b>33</b>(4): 703–13. <a target=xrefwindow id=d25988e3836 href="http://www.ncbi.nlm.nih.gov/pubmed/26433843">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3839 href="http://dx.doi.org/10.1016/j.det.2015.05.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726568338">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725804083"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3852 class=n-a></a>Goddard AL, Vleugels RA, LeBoeuf NR, <i> et al.</i>: Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy. <i>JAMA Dermatol.</i> 2015; <b>151</b>(12): 1354–7. <a target=xrefwindow id=d25988e3863 href="http://www.ncbi.nlm.nih.gov/pubmed/26397774">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3866 href="http://dx.doi.org/10.1001/jamadermatol.2015.3028">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725804083">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d25988e3879 class=n-a></a>Elsayad K, Kriz J, Moustakis C, <i> et al.</i>: Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. <i>Int J Radiat Oncol Biol Phys.</i> 2015; <b>93</b>(5): 1077–86. <a target=xrefwindow id=d25988e3890 href="http://www.ncbi.nlm.nih.gov/pubmed/26581145">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3893 href="http://dx.doi.org/10.1016/j.ijrobp.2015.08.041">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d25988e3902 class=n-a></a>Gamsiz H, Beyzadeoglu M, Sager O, <i> et al.</i>: Evaluation of mycosis fungoides management by total skin electron beam therapy with "translational technique". <i>J BUON.</i> 2015; <b>20</b>(4): 1124–31. <a target=xrefwindow id=d25988e3913 href="http://www.ncbi.nlm.nih.gov/pubmed/26416066">PubMed Abstract </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725743643"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e3922 class=n-a></a>Salva KA, Wood GS: Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma. <i>Photochem Photobiol.</i> 2015; <b>91</b>(6): 1444–51. <a target=xrefwindow id=d25988e3930 href="http://www.ncbi.nlm.nih.gov/pubmed/26302991">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3933 href="http://dx.doi.org/10.1111/php.12521">Publisher Full Text </a> | <a target=xrefwindow id=d25988e3936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4631697">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725743643">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d25988e3949 class=n-a></a>Zic JA: Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome. <i>Dermatol Clin.</i> 2015; <b>33</b>(4): 765–76. <a target=xrefwindow id=d25988e3957 href="http://www.ncbi.nlm.nih.gov/pubmed/26433848">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3960 href="http://dx.doi.org/10.1016/j.det.2015.05.011">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d25988e3970 class=n-a></a>Oka T, Sugaya M, Cury-Martins J, <i> et al.</i>: Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. <i>J Dermatol.</i> 2016; <b>43</b>(6): 638–42. <a target=xrefwindow id=d25988e3981 href="http://www.ncbi.nlm.nih.gov/pubmed/26602996">PubMed Abstract </a> | <a target=xrefwindow id=d25988e3984 href="http://dx.doi.org/10.1111/1346-8138.13199">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d25988e3993 class=n-a></a>Hosing C, Bassett R, Dabaja B, <i> et al.</i>: Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. <i>Ann Oncol.</i> 2015; <b>26</b>(12): 2490–5. <a target=xrefwindow id=d25988e4004 href="http://www.ncbi.nlm.nih.gov/pubmed/26416896">PubMed Abstract </a> | <a target=xrefwindow id=d25988e4007 href="http://dx.doi.org/10.1093/annonc/mdv473">Publisher Full Text </a> | <a target=xrefwindow id=d25988e4011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4855245">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725453797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25988e4020 class=n-a></a>Witzig TE, Reeder C, Han JJ, <i> et al.</i>: The mTORC1 inhibitor everolimus has antitumor activity <i>in vitro</i> and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood.</i> 2015; <b>126</b>(3): 328–35. <a target=xrefwindow id=d25988e4034 href="http://www.ncbi.nlm.nih.gov/pubmed/25921059">PubMed Abstract </a> | <a target=xrefwindow id=d25988e4038 href="http://dx.doi.org/10.1182/blood-2015-02-629543">Publisher Full Text </a> | <a target=xrefwindow id=d25988e4041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4504947">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725453797">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d25988e4054 class=n-a></a>Rozati S, Kim YH: Experimental treatment strategies in primary cutaneous T-cell lymphomas. <i>Curr Opin Oncol.</i> 2016; <b>28</b>(2): 166–71. <a target=xrefwindow id=d25988e4062 href="http://www.ncbi.nlm.nih.gov/pubmed/26844985">PubMed Abstract </a> | <a target=xrefwindow id=d25988e4065 href="http://dx.doi.org/10.1097/CCO.0000000000000272">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d25988e4074 class=n-a></a>Talpur R, Sui D, Gangar P, <i> et al.</i>: Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. <i>Clin Lymphoma Myeloma Leuk.</i> 2016; <b>16</b>(1): 49–56. <a target=xrefwindow id=d25988e4085 href="http://www.ncbi.nlm.nih.gov/pubmed/26702474">PubMed Abstract </a> | <a target=xrefwindow id=d25988e4088 href="http://dx.doi.org/10.1016/j.clml.2015.11.010">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d25988e4097 class=n-a></a>Jankowska-Konsur A, Kobierzycki C, Reich A, <i> et al.</i>: Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. <i>Anticancer Res.</i> 2015; <b>35</b>(11): 6017–26. <a target=xrefwindow id=d25988e4108 href="http://www.ncbi.nlm.nih.gov/pubmed/26504025">PubMed Abstract </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d25988e4118 class=n-a></a>Lee HS, Suh KS, Lee DY, <i> et al.</i>: Cutaneous Lymphoma in Korea: A Nationwide Retrospective Study. <i>Acta Derm Venereol.</i> 2016; <b>96</b>(4): 535–9. <a target=xrefwindow id=d25988e4129 href="http://www.ncbi.nlm.nih.gov/pubmed/26560051">PubMed Abstract </a> | <a target=xrefwindow id=d25988e4132 href="http://dx.doi.org/10.2340/00015555-2283">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jul 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-1882.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-1882.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Taha Physicians' Building, Khoramshahr, Khuzestan Province, Iran<br/> <sup>2</sup> Department of Dermatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-1882/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 28 Jul 2016, 5:1882 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.8829.1">https://doi.org/10.12688/f1000research.8829.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Bagherani N and Smoller BR. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9504 data-id=8829 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8829.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-1882/v1/pdf?article_uuid=070b238f-64d8-44d0-847f-33ff210a1f0a" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.8829.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bagherani N and Smoller BR. An overview of cutaneous T cell lymphomas [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1882 (<a href="https://doi.org/10.12688/f1000research.8829.1" target=_blank>https://doi.org/10.12688/f1000research.8829.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=8829 id=mobile-track-article-signin-8829 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8829?target=/articles/5-1882.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9504 /> <input name=articleId type=hidden value=8829 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Mary Jo Lechowicz</strong>, Department of Hematology Oncology, Winship Cancer Institute, Emory University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stefano A. Pileri</strong>, Unit of Haematopathology, European Institute of Oncology, Milan/Bologna University School of Medicine, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jul 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-1882.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-1882.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=15892-14987></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=15891-14988></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-1882/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>28 Jul 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Mary Jo Lechowicz</strong>, Department of Hematology Oncology, Winship Cancer Institute, Emory University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stefano A. Pileri</strong>, Unit of Haematopathology, European Institute of Oncology, Milan/Bologna University School of Medicine, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-1882.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-1882/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "An overview of cutaneous T cell lymphomas".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-1882/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-1882/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-1882/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bagherani N and Smoller BR');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-1882/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-1882",
            templates : {
                twitter : "An overview of cutaneous T cell lymphomas. Bagherani N and Smoller BR, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-1882/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: An overview of cutaneous T cell lymphomas", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: An overview of cutaneous T cell lymphomas", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/8829/9504")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9504");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "14987": 0,
                           "14988": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d381f223-a98d-4152-8f1c-7f93997f7bd3";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1882.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1882.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1882.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-1882.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-1882.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>